A Phase 3 interventional study of Cetuximab and FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) in Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 154 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-30.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.
Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 6th largest by enrollment of the 185 interventional ones that give a count, is one of 10 that started in 2004, is one of 29 in phase 3, and was the 15th registered.
6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.
Browse Colorectal Neoplasms studies →35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Verastem, Inc. · Sites in United States, Australia, Belgium and 2 more countries
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 131 · Phase 3 33 · Phase 4 4
First in 1999; this study’s year is marked. 10 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,221 is above the median of 76 across 4,810 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 60 across the 185 interventional studies. Of the 108 that completed or were terminated, 29 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 187 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
21 studies in Colorectal Neoplasms by Merck KGaA, Darmstadt, Germany: 1 open now, 2 under way, 1 of them phase 3. Of 19 finished, 10 (53%) have results posted.
Among the 21 studies in Colorectal Neoplasms by Merck KGaA, Darmstadt, Germany, this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2004, is one of 3 in phase 3, and was the 3rd registered.
Merck KGaA, Darmstadt, Germany’s Colorectal Neoplasms studies by the year they started, since 2004.
6 of the studies testing cetuximab in Colorectal Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06226857Phase 3City Clinical Oncology Hospital No 1Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer | 2026-12-31 |
| NCT06321081Beijing HospitalICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC | 2026-12-30 |
| NCT05706779Federation Francophone de Cancerologie DigestiveEncorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer | 2026-12-30 |
| NCT06411600Vall d'Hebron Institute of OncologyCombination Therapy for BRAF-V600E Metastatic CRCm | 2027-05-01 |
| NCT07659795Verastem, Inc.A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 187 studies testing cetuximab in Colorectal Neoplasms, from their registry updates:
Among Merck KGaA, Darmstadt, Germany’s 21 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
Drugs used against cancer work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Giving combination chemotherapy together with cetuximab as first treatment after diagnosis of a metastatic colorectal cancer ('1st-line' treatment) may improve the treatment efficacy. However, it is not yet known whether giving combination chemotherapy together with cetuximab is more effective than combination chemotherapy alone. This open-label trial investigates the effectiveness of cetuximab in combination with a standard and effective chemotherapy (5-Fluorouracil (5FU)/Folinic acid (FA) plus irinotecan) for metastatic colorectal cancer in first-line setting, compared to the same chemotherapy alone on patient expressing the epidermal growth factor (EGF) receptor.
Patients expressing this EGF Receptor will be randomly assign in one of the 2 groups to either receive the combination chemotherapy alone or with cetuximab (open-label study) and will then be treated until progression of the disease or unacceptable toxicity occur. Regular efficacy assessments (every 8 weeks) based on imaging will be performed throughout the study together with regular safety assessments (e.g. safety labs). An independent Safety Board of experts will also monitor safety data.
After participant discontinuation from the trial, regular updates on further treatments and survival status will be requested from the investigator.
The entire study (from the first patient entering the study to the last collect of follow-up information) is 4-5 years long.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Cetuximab · Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
Cetuximab intravenous infusion of 400mg/m\^2 for the first infusion then weekly intravenous infusion of 250mg/m\^2. Number of Cycles: until progression or unacceptable toxicity develops
Bi-weekly Irinotecan infusion of 180mg/m\^2, Folinic Acid infusion of 400mg/m\^2 (racemic) or 200mg/m\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\^2 followed by a 46-hour continuous infusion of 2400mg/m\^2 Number of Cycles: until progression or unacceptable toxicity develops
Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments
Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.
Time frame: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Progression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments
Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.
Time frame: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments
Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.
Time frame: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Overall Survival Time (OS)
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.
Time frame: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
Overall Survival Time (KRAS Wild-Type Population)
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.
Time frame: Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
Overall Survival Time (KRAS Mutant Population)
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.
Time frame: Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
Best Overall Response Rate - Independent Review Committee (IRC) Assessments
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).
Time frame: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Best Overall Response Rate (KRAS Wild-Type Population) - Independent Review Committee (IRC) Assessments
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).
Time frame: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Best Overall Response Rate (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).
Time frame: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Disease Control Rate - Independent Review Committee (IRC) Assessments
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria).
Time frame: Evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Duration of Response - Independent Review Committee (IRC) Assessments
Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment). Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.
Time frame: Time from first assessment of complete response or partial response to disease progression, death or last tumor assessment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Participants With No Residual Tumor After Metastatic Surgery
Participants with no residual tumor after on-study surgery for metastases
Time frame: time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007
Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status
Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.
Time frame: at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Quality of Life Assessment (EORTC QLQ-C30) Social Functioning
Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning.
Time frame: at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
Safety - Number of Patients Experiencing Any Adverse Event
Please refer to Adverse Events section for further details
Time frame: time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007
First/Last subject in: 10 Aug 2004/4 Nov 2005. Clinical cut-off efficacy analyses except survival: 27 Jul 2006, Cut off date IRC data: 14 Dec 2006; cut-off safety analyses: 30 Nov 2007; cut-off survival analyses: 31 May 2009; cut-off KRAS analyses: 28 Aug 2009. 1221 subjects were randomised or treated, of whom 1198 were randomised and treated.
| Milestone | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| Started | 599 | 599 |
| Completed | 592 | 597 |
| Not completed | 7 | 2 |
| Withdrew: Investigational study phase ongoing | 7 | 2 |
Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.
| months | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments | 8.9 (8.0 to 9.4) | 8.0 (7.6 to 9.0) |
Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.
| months | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| Progression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments | 9.9 (9.0 to 11.3) | 8.4 (7.4 to 9.2) |
Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.
| months | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments | 7.4 (6.1 to 8.0) | 7.7 (7.3 to 9.2) |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.
| months | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| Overall Survival Time (OS) | 19.9 (18.5 to 21.3) | 18.6 (16.7 to 19.8) |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.
| months | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| Overall Survival Time (KRAS Wild-Type Population) | 23.5 (21.2 to 26.3) | 20.0 (17.4 to 21.7) |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.
| months | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| Overall Survival Time (KRAS Mutant Population) | 16.2 (14.9 to 17.9) | 16.7 (14.9 to 19.4) |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).
| percentage of participants | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| Best Overall Response Rate - Independent Review Committee (IRC) Assessments | 46.9 (42.9 to 51.0) | 38.7 (34.8 to 42.8) |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).
| percentage participants | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| Best Overall Response Rate (KRAS Wild-Type Population) - Independent Review Committee (IRC) Assessments | 57.3 (51.6 to 62.8) | 39.7 (34.6 to 45.1) |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).
| percentage of participants | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| Best Overall Response Rate (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments | 31.3 (25.2 to 38.0) | 36.1 (29.1 to 43.5) |
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria).
| percentage of participants | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| Disease Control Rate - Independent Review Committee (IRC) Assessments | 84.3 (81.1 to 87.1) | 85.5 (82.4 to 88.2) |
Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment). Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.
| months | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| Duration of Response - Independent Review Committee (IRC) Assessments | 9.6 (9.1 to 12.9) | 7.7 (6.7 to 8.3) |
Participants with no residual tumor after on-study surgery for metastases
| Participants | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| Participants With No Residual Tumor After Metastatic Surgery | 29 | 10 |
Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.
| scores on a scale | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| At baseline | 58.88 ± 1.185 | 60.33 ± 1.155 |
| At week 8 | 59.02 ± 1.187 | 61.83 ± 1.176 |
| At week 16 | 60.77 ± 1.276 | 63.29 ± 1.249 |
| At week 24 | 61.83 ± 1.368 | 64.06 ± 1.364 |
| At week 32 | 59.68 ± 1.590 | 65.07 ± 1.612 |
| At week 40 | 63.43 ± 1.835 | 64.02 ± 1.991 |
Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning.
| scores on a scale | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| At baseline | 75.21 ± 1.426 | 77.28 ± 1.395 |
| At week 8 | 74.14 ± 1.430 | 76.71 ± 1.415 |
| At week 16 | 73.72 ± 1.533 | 76.67 ± 1.498 |
| At week 24 | 76.31 ± 1.644 | 77.98 ± 1.633 |
| At week 32 | 74.04 ± 1.903 | 75.64 ± 1.933 |
| At week 40 | 76.58 ± 2.198 | 78.07 ± 2.388 |
Please refer to Adverse Events section for further details
| participants | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| Safety - Number of Patients Experiencing Any Adverse Event | 599 | 597 |
Collected over Time from first dose up to 30 days after the last dose of study treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cetuximab Plus FOLFIRI | — | 263/600 (43.8%) | 593/600 (98.8%) |
| FOLFIRI Alone | — | 204/602 (33.9%) | 591/602 (98.2%) |
| Event | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 37/600 | 35/602 |
| DIARRHOEAGastrointestinal disorders | 36/600 | 21/602 |
| PYREXIAGeneral disorders | 26/600 | 21/602 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 20/600 | 10/602 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 16/600 | 13/602 |
| DEHYDRATIONMetabolism and nutrition disorders | 16/600 | 12/602 |
| VOMITINGGastrointestinal disorders | 15/600 | 16/602 |
| ABDOMINAL PAINGastrointestinal disorders | 14/600 | 13/602 |
| HYPOMAGNESAEMIAMetabolism and nutrition disorders | 13/600 | 1/602 |
| ILEUSGastrointestinal disorders | 10/600 | 7/602 |
| Event | Cetuximab Plus FOLFIRI | FOLFIRI Alone |
|---|---|---|
| DIARRHOEAGastrointestinal disorders | 377/600 | 353/602 |
| NAUSEAGastrointestinal disorders | 322/600 | 359/602 |
| NEUTROPENIABlood and lymphatic system disorders | 272/600 | 249/602 |
| RASHSkin and subcutaneous tissue disorders | 270/600 | 23/602 |
| VOMITINGGastrointestinal disorders | 194/600 | 231/602 |
| ALOPECIASkin and subcutaneous tissue disorders | 224/600 | 229/602 |
| FATIGUEGeneral disorders | 192/600 | 186/602 |
| STOMATITISGastrointestinal disorders | 169/600 | 110/602 |
| ANOREXIAMetabolism and nutrition disorders | 169/600 | 149/602 |
| ABDOMINAL PAINGastrointestinal disorders | 142/600 | 154/602 |
| Age, Continuous(years) | Cetuximab Plus FOLFIRI | FOLFIRI Alone | Total |
|---|---|---|---|
| Mean | 60.0 ± 10.52 | 59.8 ± 11.06 | 59.9 ± 10.79 |
| Age, Customized(participants) | Cetuximab Plus FOLFIRI | FOLFIRI Alone | Total |
|---|---|---|---|
| Missing | 1 | 0 | 1 |
| Between 18 and 65 years | 374 | 377 | 751 |
| >=65 years | 224 | 222 | 446 |
| Gender(Participants) | Cetuximab Plus FOLFIRI | FOLFIRI Alone | Total |
|---|---|---|---|
| Female | 230 | 243 | 473 |
| Male | 369 | 356 | 725 |
| Region of Enrollment(participants) | Cetuximab Plus FOLFIRI | FOLFIRI Alone | Total |
|---|---|---|---|
| Western Europe | 262 | 267 | 529 |
| Eastern Europe | 203 | 201 | 404 |
| Rest of the World | 134 | 131 | 265 |
Showing the first 100 of 154 sites across 30 countries. Choose a country and city above to see the rest.
The record gives a start of May 2004, a primary completion of Dec 2006 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetuximab
Merck KGaA, Darmstadt, Germany →